Novavax, Inc (NASDAQ: NVAX)’s stock price has gone decline by -7.29 in comparison to its previous close of 7.00, however, the company has experienced a -15.60% decrease in its stock price over the last five trading days. cnbc.com reported 2025-03-31 that Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Human Services Secretary Robert F.
Is It Worth Investing in Novavax, Inc (NASDAQ: NVAX) Right Now?
NVAX has 36-month beta value of 3.10. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NVAX is 146.57M, and currently, short sellers hold a 25.62% ratio of that float. The average trading volume of NVAX on March 31, 2025 was 4.25M shares.
NVAX’s Market Performance
The stock of Novavax, Inc (NVAX) has seen a -15.60% decrease in the past week, with a -22.09% drop in the past month, and a -23.38% fall in the past quarter. The volatility ratio for the week is 3.64%, and the volatility levels for the past 30 days are at 6.23% for NVAX. The simple moving average for the past 20 days is -16.31% for NVAX’s stock, with a -38.40% simple moving average for the past 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with BTIG Research repeating the rating for NVAX by listing it as a “Buy.” The predicted price for NVAX in the upcoming period, according to BTIG Research is $19 based on the research report published on February 28, 2025 of the current year 2025.
JP Morgan, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $8. The rating they have provided for NVAX stocks is “Underweight” according to the report published on July 30th, 2024.
NVAX Trading at -19.86% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.80% of loss for the given period.
Volatility was left at 6.23%, however, over the last 30 days, the volatility rate increased by 3.64%, as shares sank -17.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.86% lower at present.
During the last 5 trading sessions, NVAX fell by -15.55%, which changed the moving average for the period of 200-days by -61.17% in comparison to the 20-day moving average, which settled at $7.75. In addition, Novavax, Inc saw -19.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVAX starting from King Rachel K., who sale 4,150 shares at the price of $9.02 back on Dec 13 ’24. After this action, King Rachel K. now owns 14,770 shares of Novavax, Inc, valued at $37,435 using the latest closing price.
YOUNG JAMES F, the Director of Novavax, Inc, sale 5,400 shares at $8.00 during a trade that took place back on Dec 31 ’24, which means that YOUNG JAMES F is holding 51,760 shares at $43,200 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.73 for the gross margin
The net margin for Novavax, Inc stands at -0.27. The total capital return value is set at -0.6.
Based on Novavax, Inc (NVAX), the company’s capital structure generated -0.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.38. The debt to equity ratio resting at -0.37. The interest coverage ratio of the stock is -12.1.
Currently, EBITDA for the company is -108.04 million with net debt to EBITDA at 2.77. When we switch over and look at the enterprise to sales, we see a ratio of 1.1. The receivables turnover for the company is 6.3for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.98.
Conclusion
To put it simply, Novavax, Inc (NVAX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
